A recent decline in breast cancer incidence is unlikely to be caused by a decrease in mammography screening, according to a study published online August 14 in the Journal of the National Cancer Institute. It is more likely due to the drop in postmenopausal hormone use.
Artificially inducing menopause may reduce breast cancer recurrence in premenopausal women with early-stage breast cancers.
Blood clots are a leading cause of disability and death in patients following surgery, despite medical advances in their prevention, diagnosis, and treatment.
A rise in breast cancer incidence from the 1980s through 2001 paralleled trends in mammography screening and hormone therapy use, while a recent decline in incidence was consistent with a drop in hormone therapy use, according to a study of a large group of women enrolled in a single health plan,.
The medical community has been debating for many years whether, and to what extent, postmenopausal hormone therapy (HT) use is associated with a higher risk of breast cancer, says Professor Amos Pines, President of the International Menopause Society.
Growth hormone injections appear to boost height in extremely short, healthy children, according to a recent systematic review, but height gain appears to peak at about three inches ? and those inches are expensive.
New evidence published on bmj.com confirms that hormone replacement therapy (HRT) should not be prescribed to older women who are many years past menopause to help prevent chronic conditions such as heart disease.
For prostate cancer patients whose tumors have continued to grow despite medical or surgical castration, a new drug candidate that inhibits production of male hormones anywhere in the body is showing promise in early trials.
Acrux (ASX: ACR) – The Australian drug delivery company, today announced positive results from its Phase 1 clinical studies using two unique contraceptive skin sprays, each containing a progestin and an estrogen.
Cyclical, long-term estrogen injections protected brain cells from age-related deterioration, according to a new study conducted at Mount Sinai School of Medicine. The study suggests that age is a factor in estrogen treatment and sheds light on the intricate relationship between mind, age, and hormones. The study will be published in the online edition of Proceedings of the National Academy of Sciences during the week of June 25.